Claims
- 1. A compound of formula I: or a stereoisomer or pharmaceutically acceptable salt form thereof, wherein;A is selected from —COR5, —CO2H, CH2CO2H, —CO2R6, —CONHOH, —CONHOR5, —CONHOR6, —N(OH)CHO, —N(OH)COR5, —SH, —CH2SH, —SONHRa, —SN2H2Ra, —PO(OH)2, and —PO(OH)NHRa; ring B is a 5-6 membered heterocyclic ring consisting of: carbon atoms, 0-1 carbonyl groups, 0-1 double bonds, and from 0-2 ring heteroatoms selected from O, N, NR2, and S(O)p, provided that ring B contains other than a S—S, O—O, or O—O, or S—O bond and provided that N—R2 forms other than an N—O, N—N, or N—S bond; Z is phenyl substituted with 0-4 Rb; Ua is O; Xa is absent or selected from C1-10 alkylene, C2-10 alkenylene, and C2-10 alkynylene; Ya is absent or selected from O, NRa1, S(O)p, and C(O); Za isquinolinyl substituted with 0-5 Rc; provided that Z, Ua, Ya, and Za do not combine to form a O—N, O—O, or O—S(O)p group; R1a is selected from H, C1-4 alkyl, phenyl, benzyl, CH2OR3, and CH2NRaRa1; R1b is selected from H, C1-4 alkyl, phenyl, benzyl, CH2OR3, and CH2NRaRa1; alternatively, R1a and R1b combine to form a 3-6 membered ring consisting of: carbon atoms and 0-1 heteroatoms selected from O, S, S(O), S(O)2, and NRa; provided that when R1a and R1b are hydrogen and ring B is a heterocycle, then Za is the following: ring C is phenyl or pyridyl and is substituted with 0-2 Rc; ring D is selected from phenyl, pyridyl, pyridazinyl, pyrimidyl, and pyrazinyl, and is substituted with 0-3 Rc; R2 is selected from Q, C1-10 alkylene-Q substituted with 0-3 Rb1, C2-10 alkenylene-Q substituted with 0-3 Rb1, C2-10 alkynylene-Q substituted with 0-3 Rb1, (CRaRa1)r1O(CRaRa1)r-Q, (CRaRa1)r1NRa(CRaRa1)r-Q, (CRaRa1)r1C(O)(CRaRa1)r-Q, (CRaRa1)r1C(O)O(CRaRa1)r-Q, (CRaRa1)r1OC(O)(CRaRa1)r-Q, (CRaRa1)r1C(O)NRaRa1; (CRaRa1)r1C(O)NRa(CRaRa1)r-Q, (CRaRa1)r1NRaC(O)(CRaRa1)r-Q, (CRaRa1)r1OC(O)O(CRaRa1)r-Q, (CRaRa1)r1OC(O)NRa(CRaRa1)r-Q, (CRaRa1)r1NRaC(O)O(CRaRa1)r-Q, (CRaRa1)r1NRaC(O)NRa(CRaRa1)r-Q, (CRaRa1)r1S(O)p(CRaRa1)r-Q, (CRaRa1)r1SO2NRa(CRaRa1)r-Q, (CRaRa1)r1NRaSO2(CRaRa1)r-Q, and (CRaRa1)r1NRaSO2NRa(CRaRa1)r-Q; R2a is selected from H, C1-14 alkyl, phenyl, benzyl, CH2OR3, and CH2NRaRa1; R2b is selected from H, C1-4 alkyl, phenyl, benzyl, CH2OR3, and CH2NRaRa1; alternatively, R2a and R2b combine to form a 3-6 membered ring consisting of: carbon atoms and 0-1 heteroatoms selected from O, S, S(O), S(O)2, and NRa; Q is selected from H, a C3-13 carbocyclic residue substituted with 0-5 Rd and a 5-14 membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)p and substituted with 0-5 Rd; R3, at each occurrence, is selected from Q1, C1-6 alkylene-Q1, C2-6 alkenylene-Q1, C2-6 alkynylene-Q1, (CRaRa1)r1O(CH2)r-Q1, (CRaRa1)r1NRa(CRaRa1)r-Q1, (CRaRa1)r1NRaC(O)(CRaRa1)r-Q1, (CRaRa1)r1C(O)NRa(CRaRa1)r-Q1, (CRaRa1)r1C(O)(CRaRa1)r-Q1, (CRaRa1)r1C(O)O(CRaRa1)r-Q1, (CRaRa12)r1S(O)p(CRaRa1)r-Q1, and (CRaRa1)r1SO2NRa(CRaRa1)r-Q1; alternatively, when two R3's are attached to the same carbon atom, they combine to form a 3-8 membered carbocyclic or heterocyclic ring consisting of: carbon atoms and 0-3 heteroatoms selected from the group consisting of N, O, and S(O)p and substituted with 0-3 Rd; Q1 is selected from H, phenyl substituted with 0-3 Rd, naphthyl substituted with 0-3 Rd and a 5-10 membered heteroaryl consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S and substituted with 0-3 Rd; Ra, at each occurrence, is independently selected from H, C1-4 alkyl, phenyl and benzyl; Ra1, at each occurrence, is independently selected from H and C1-4 alkyl; alternatively, Ra and Ra1 when attached to a nitrogen are taken together with the nitrogen to which they are attached to form a 5 or 6 membered ring comprising carbon atoms and from 0-1 additional heteroatoms selected from the group consisting of N, O, and S(O)p; Ra2, at each occurrence, is independently selected from C1-4 alkyl, phenyl and benzyl; Rb, at each occurrence, is independently selected from C1-6 alkyl, ORa, Cl, F, Br, I, ═O, —CN, NO2, NRaRa1, C(O)Ra, C(O)ORa, C(O)NRaRa1, RaNC(O)NRaRa1, OC(O)NRaRa1, RaNC(O)O, S(O)2NRaRa1, NRaS(O)2Ra2, NRaS(O)2NRaRa1, OS(O)2NRaRa1, NRaS(O)2Ra2, S(O)pRa2, CF3, and CF2CF3; Rb1, at each occurrence, is independently selected from ORa, Cl, F, Br, I, ═O, —CN, NO2, and NRaRa1; Rc, at each occurrence, is independently selected from C1-6 alkyl, ORa, Cl, F, Br, I, ═O, —CN, NO2, NRaRa1, C(O)Ra, C(O)ORa, C(O)NRaRa1, RaNC(O)NRaRa1, OC(O)NRaRa1, RaNC(O)O, S(O)2NRaRa1, NRaS(O)2Ra2, NRaS(O)2NRaRa1, OS(O)2NRaRa1, NRaS(O)2Ra2, S(O)pRa2, CF3, CF2CF3, C3-10 carbocyclic residue and a 5-14 membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)p; Rd, at each occurrence, is independently selected from C1-6 alkyl, ORa, Cl, F, Br, I, ═O, —CN, NO2, NRaRa1, C(O)Ra, C(O)ORa, C(O)NRaRa1, RaNC(O)NRaRa1, OC(O)NRaRa1, RaNC(O)O, S(O)2NRaRa1, NRaS(O)2Ra2, NRaS(O)2NRaRa1, OS(O)2NRaRa1, NRaS(O)2Ra2, S(O)pRa2, CF3, CF2CF3, C3-10 carbocyclic residue and a 5-14 membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)p; R5, at each occurrence, is selected from C1-10 alkyl substituted with 0-2 Rb, and C1-8 alkyl substituted with 0-2 Re; Re, at each occurrence, is selected from phenyl substituted with 0-2 Rb and biphenyl substituted with 0-2 Rb; R6, at each occurrence, is selected from phenyl, naphthyl, C1-10 alkyl-phenyl-C1-6 alkyl-, C3-11 cycloalkyl, C1-6 alkylcarbonyloxy-C1-3 alkyl-, C1-6 alkoxycarbonyloxy-C1-3 alkyl-, C2-10 alkoxycarbonyl, C3-6 cycloalkylcarbonyloxy-C1-3 alkyl-, C3-6 cycloalkoxycarbonyloxy-C1-3 alkyl-, C3-6 cycloalkoxycarbonyl, phenoxycarbonyl, phenyloxycarbonyloxy-C1-3 alkyl-, phenylcarbonyloxy-C1-3 alkyl-, C1-6 alkoxy-C1-6 alkylcarbonyloxy-C1-3 alkyl-, [5-(C1-C5 alkyl)-1,3-dioxa-cyclopenten-2-one-yl]methyl, [5-(Ra)-1,3-dioxa-cyclopenten-2-one-yl]methyl, (5-aryl-1,3-dioxa-cyclopenten-2-one-yl)methyl, —C1-10 alkyl-NR7R7a, —CH(R8)OC(═O)R9, and —CH(R8)OC(═O)OR9; R7 is selected from H and C1-10 alkyl, C2-6 alkenyl, C3-6 cycloalkyl-C1-3 alkyl-, and phenyl-C1-6 alkyl-; R7a is selected from H and C1-10 alkyl, C2-6 alkenyl, C3-6 cycloalkyl-C1-3 alkyl-, and phenyl —C1-6 alkyl-; R8 is selected from H and C1-4 linear alkyl; R9 is selected from H, C1-8 alkyl substituted with 1-2 Rf, C3-8 cycloalkyl substituted with 1-2 Rf, and phenyl substituted with 0-2 Rb; Rf, at each occurrence, is selected from C1-4 alkyl, C3-8 cycloalkyl, C1-5 alkoxy, and phenyl substituted with 0-2 Rb; p, at each occurrence, is selected from 0, 1, and 2; p1 is selected from 0, 1, and 2; r, at each occurrence, is selected from 0, 1, 2, 3, and 4; and, r1, at each occurrence, is selected from 0, 1, 2, 3, and 4.
- 2. A compound according to claim 1, wherein the compound is of formula II: or a stereoisomer or pharmaceutically acceptable salt form thereof, wherein;A is selected from —CO2H, CH2CO2H, —CONHOH, —CONHOR5, —CONHOR6, —N(OH)CHO, —N(OH)COR5, —SH, and —CH2SH; ring B is a 5-6 membered heterocyclic ring consisting of: carbon atoms, 0-1 carbonyl groups, 0-1 doublebonds, and from 0-2 ring heteroatoms selected from O, N, and NR2, provided that ring B contains other than an O—O bond and provided that N—R2 forms other than an N—O, N—N, or N—S bond; Xa is absent or selected from C1-4 alkylene and C2-4 alkynylene; Ya is absent or selected from O and NRa1; provided that Z, Ua, Ya, and Za do not combine to form a O—N or O—O group; R2 is selected from Q, C1-6 alkylene-Q, C2-6 alkenylene-Q, C2-6 alkynylene-Q, (CRaRa1)r1O(CRaRa1)r-Q, (CRaRa1)r1NRa(CRaRa1)r-Q, (CRaRa1)r1C(O)CRaRa1)r-Q, (CRaRa1)r1C(O)O(CRaRa1)r-Q, (CRaRa1)rC(O)NRaRa1, (CRaRa1)r1C(O)NRa(CRaRa1)r-Q, (CRaRa1)r1S(O)p(CRaRa1)r-Q, and (CRaRa1)r1SO2NRa(CRaRa1)r-Q; Q is selected from H, a C3-6 carbocyclic residue substituted with 0-5 Rd, and a 5-10 membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)p and substituted with 0-5 Rd; Ra, at each occurrence, is independently selected from H, C1-4 alkyl, phenyl and benzyl; Ra1, at each occurrence, is independently selected from H and C1-4 alkyl; alternatively, Ra and Ra1 when attached to a nitrogen are taken together with the nitrogen to which they are attached to form a 5 or 6 membered ring comprising carbon atoms and from 0-1 additional heteroatoms selected from the group consisting of N, O, and S(O)p; Ra2, at each occurrence, is independently selected from C1-4 alkyl, phenyl and benzyl; Rb, at each occurrence, is independently selected from C1-6 alkyl, ORa, Cl, F, Br, ═O, —CN, NRaRa1, C(O)Ra, C(O)ORa, C(O)NRaRa1, S(O)2NRaRa1, S(O)pRa2, and CF3; Rc, at each occurrence, is independently selected from C1-6 alkyl, ORa, Cl, F, Br, ═O, —CN, NRaRa1, C(O)Ra, C(O)ORa, C(O)NRaRa1, S(O)2NRaRa1, S(O)pRa2, CF3, C3-6 carbocyclic residue and a 5-6 membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)p; Rd, at each occurrence, is independently selected from C1-6 alkyl, ORa, Cl, F, Br, ═O, —CN, NRaRa1, C(O)Ra, C(O)ORa, C(O)NRaRa1, S(O)2NRaRa1, S(O)pRa2, CF3, C3-6 carbocyclic residue and a 5-6 membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)p; R5, at each occurrence, is selected from C1-6 alkyl substituted with 0-2 Rb, and C1-4 alkyl substituted with 0-2 Re; Re, at each occurrence, is selected from phenyl substituted with 0-2 Rb and biphenyl substituted with 0-2 Rb; R6, at each occurrence, is selected from phenyl, naphthyl, C1-10 alkyl-phenyl-C1-6 alkyl-, C3-11 cycloalkyl, C1-6 alkylcarbonyloxy-C1-3 alkyl-, C1-6 alkoxycarbonyloxy-C1-3 alkyl-, C2-10 alkoxycarbonyl, C3-6 cycloalkylcarbonyloxy-C1-3 alkyl-, C3-6 cycloalkoxycarbonyloxy-C1-3 alkyl-, C3-6 cycloalkoxycarbonyl, phenoxycarbonyl, phenyloxycarbonyloxy-C1-3 alkyl-, phenylcarbonyloxy-C1-3 alkyl-, C1-6 alkoxy-C1-6 alkylcarbonyloxy-C1-3 alkyl-, [5-(C1-C5 alkyl)-1,3-dioxa-cyclopenten-2-one-yl]methyl, [5-(Ra)-1,3-dioxa-cyclopenten-2-one-yl]methyl, (5-aryl-1,3-dioxa-cyclopenten-2-one-yl)methyl, —C1-10 alkyl-NR7R7a, —CH(R8)OC(═O)R9, and —CH(R8)OC(═O)OR9; R7 is selected from H and C1-6 alkyl, C2-6 alkenyl, C3-6 cycloalkyl-C1-3 alkyl-, and phenyl-C1-6 alkyl-; R7a is selected from H and C1-6 alkyl, C2-6 alkenyl, C3-6 cycloalkyl-C1-3 alkyl-, and phenyl-C1-6 alkyl-; R8 is selected from H and C1-4 linear alkyl; R9 is selected from H, C1-6 alkyl substituted with 1-2 Rf, C3-6 cycloalkyl substituted with 1-2 Rf, and phenyl substituted with 0-2 Rb; Rf, at each occurrence, is selected from C1-4 alkyl, C3-6 cycloalkyl, C1-5 alkoxy, and phenyl substituted with 0-2 Rb; p, at each occurrence, is selected from 0, 1, and 2; r, at each occurrence, is selected from 0, 1, 2, 3, and 4; and, r1, at each occurrence, is selected from 0, 1, 2, 3, and 4.
- 3. A compound according to claim 2, wherein the compound is of formula III: or a stereoisomer or pharmaceutically acceptable salt form thereof, wherein;A is selected from —CO2H, CH2CO2H, —CONHOH, —CONHOR5, —N(OH)CHO, and —N(OH)COR5; B1 is NR2 or O; Z is phenyl substituted with 0-3 Rb; Xa is absent or selected from C1-2 alkylene and C2-4 alkynylene; R2 is selected from Q, C1-6 alkylene-Q, C2-6 alkenylene-Q, C2-6 alkynylene-Q, (CRaRa1)r1O(CRaRa1)r-Q, (CRaRa1)r1NRa(CRaRa1)r-Q, (CRaRa1)r1C(O)(CRaRa1)r-Q, (CRaRa1)r1C(O)O(CRaRa1)r-Q, (CRaRa2)r1C(O)NRaRa1, (CRaRa2)r1C(O)NRa(CRaRa1)r-Q, and (CRaRa1)r1S(O)p(CRaRa1)r-Q; Q is selected from H, a C3-6 carbocyclic residue substituted with 0-3 Rd and a 5-10 membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)p and substituted with 0-3 Rd; Ra, at each occurrence, is independently selected from H, C1-4 alkyl, phenyl and benzyl; Ra1, at each occurrence, is independently selected from H and C1-4 alkyl; Ra2, at each occurrence, is independently selected from C1-4 alkyl, phenyl and benzyl; Rb, at each occurrence, is independently selected from C1-4 alkyl, ORa, Cl, F, ═O, NRa1Ra1, C(O)Ra, C(O)ORa, C(O)NRaRa1, S(O)2NRaRa1, S(O)pRa2, and CF3; Rc, at each occurrence, is independently selected from C1-6 alkyl, ORa, CI, F, Br, ═O, NRaRa1, C(O)Ra, C(O)NRaRa1, S(O)2NRaRa1, S(O)pRa2, and CF3; Rd, at each occurrence, is independently selected from C1-6 alkyl, ORa, Cl, F, Br, ═O, NRaRa1, C(O)Ra, C(O)NRaRa1, S(O)2NRaRa1, S(O)pRa2, CF3 and phenyl; R5, at each occurrence, is selected from C1-4 alkyl substituted with 0-2 Rb, and C1-4 alkyl substituted with 0-2 Re; Re, at each occurrence, is selected from phenyl substituted with 0-2 Rb and biphenyl substituted with 0-2 Rb; p, at each occurrence, is selected from 0, 1, and 2; r, at each occurrence, is selected from 0, 1, 2, 3, and 4; r1, at each occurrence, is selected from 0, 1, 2, 3, and 4; and, s and s1 combine to total 1, 2, 3, or 4.
- 4. A compound according to claim 3, wherein the compound is of formula IV: or a stereoisomer or pharmaceutically acceptable salt form thereof, wherein;Z is phenyl substituted with 0-3 Rb; Xa is absent or is selected from CR2, CH2CH2, and C2-4 alkynylene; Ya is absent or is O; Za is quinolinyl substituted with 0-3 Rc; provided that Z, Ua, Ya, and Za do not combine to form a O—O group; R2 is selected from Q, C1-6 alkylene-Q, C2-6 alkynylene-Q, (CRaRa1)r1O(CRaRa1)r-Q, (CRaRa1)r1NRa(CRaRa1)r-Q, C(O)(CRaRa1)r-Q, C(O)O(CRaRa1)r-Q, C(O)NRa(CRaRa1)r-Q, and S(O)p(CRaRa1)r-Q Q is selected from H, cyclopropyl substituted with 0-1 Rd, cyclobutyl substituted with 0-1 Rd, cyclopentyl substituted with 0-1 Rd, cyclohexyl substituted with 0-1 Rd, phenyl substituted with 0-2 Rd and a heteroaryl substituted with 0-3 Rd, wherein the heteroaryl is selected from pyridyl, quinolinyl, thiazolyl, furanyl, imidazolyl, and isoxazolyl; Ra, at each occurrence, is independently selected from H, CH3, and CH2CH3; Ra1, at each occurrence, is independently selected from H, CH3, and CH2CH3; Ra2, at each occurrence, is independently selected from H, CH3, and CH2CH3; Rb, at each occurrence, is independently selected from C1-4 alkyl, ORa, Cl, F, ═O, NRaRa1, C(O)Ra, C(O)ORa, C(O)NRaRa1, S(O)2NRaRa1, S(O)pRa2, and CF3; Rc, at each occurrence, is independently selected from C1-6 alkyl, ORa, Cl, F, Br, ═O, NRaRa1, C(O)Ra, C(O)NRaRa1, S(O)2NRaRa1, S(O)pRa2, and CF3; Rd, at each occurrence, is independently selected from C1-6 alkyl, ORa, Cl, F, Br, ═O, NRaRa1, C(O)Ra, C(O)NRaRa1, S(O)2NRaRa1, S(O)pRa2, CF3 and phenyl; p, at each occurrence, is selected from 0, 1, and 2; r, at each occurrence, is selected from 0, 1, 2, and 3; r1, at each occurrence, is selected from 0, 1, 2, and 3; and, s and s1 combine to total 2, 3, or 4.
- 5. A compound according to claim 1, wherein the compound is selected from the group:N-hydroxy-2-{2-[({4-[2-methyl-4-quinolinyl)methoxy]phenyl}sulfonyl)methyl]-2-pyrrolidinyl}acetamide; N-hydroxy-2-{1-methyl-2-[({4-[(2-methyl-4-quinolinyl)methoxy]phenyl}sulfonyl)methyl]-2-pyrrolidinyl}acetamide; N-hydroxy-2-{1 -isobutyl-2-[({4-[(2-methyl-4-quinolinyl)methoxy]phenyl}sulfonyl)methyl]-2-pyrrolidinyl}acetamide; N-hydroxy-2-[2-[({4-[(2-methyl-4-quinolinyl)methoxy]phenyl}sulfonyl)methyl]-1-(3-pyridinyl)-2-pyrrolidinyl}acetamide; 2-{1-acetyl-2-[({4-[(2-methyl-4-quinolinyl)methoxy]phenyl}sulfonyl)methyl]-2-pyrrolidinyl}-N-hydroxyacetamide; N-hydroxy-2-{3-[({4-{(2-methyl-4-quinolinyl)methoxy]phenyl}sulfonyl)methyl]-3-pyrrolidinyl}acetamide; N-hydroxy-2-{1-methyl-3-[({4-{(2-methyl-4-quinolinyl)methoxy]phenyl}sulfonyl)methyl]-3-pyrrolidinyl}acetamide; N-hydroxy-2-{1-isopropyl-3-[({4-{(2-methyl-4-quinolinyl)methoxy]phenyl}sulfonyl)methyl]-3-pyrrolidinyl}acetamide; N-hydroxy-2-{1-isobutyl-3-[({4-{(2-methyl-4-quinolinyl)methoxy]phenyl}sulfonyl)methyl]-3-pyrrolidinyl}acetamide; N-hydroxy-2-{3-[({4-{(2-methyl-4-quinolinyl)methoxy]phenyl}sulfonyl)methyl]-1-neopentyl-3-pyrrolidinyl}acetamide; N-hydroxy-2-{2-[({4-[(2-methyl-4-quinolinyl)methoxy]phenyl}sulfonyl)methyl]-2-piperidinyl}acetamide; N-hydroxy-2-{1-methyl-2-[({4-[(2-methyl-4-quinolinyl)methoxy]phenyl}sulfonyl)methyl]-2-piperidinyl}acetamide; N-hydroxy-2-{1-isobutyl-2-[({4-[(2-methyl-4-quinolinyl)methoxy]phenyl}sulfonyl)methyl]-2-piperidinyl}acetamide; N-hydroxy-2-{3-[({4-[(2-methyl-4-quinolinyl)methoxy]phenyl}sulfinyl)methyl]-3-piperidinyl}acetamide; N-hydroxy-2-{1-methyl-3-[({4-[(2-methyl-4-quinolinyl)methoxy]phenyl}sulfinyl)methyl]-3-piperidinyl}acetamide N-hydroxy-2-{1-isopropyl-3-[({4-[(2-methyl-4-quinolinyl)methoxy]phenyl}sulfinyl)methyl]-3-piperidinyl}acetamide; N-hydroxy-2-{3-[({4-[(2-methyl-4-quinolinyl)methoxy]phenyl}sulfonyl)methyl]-3-piperidinyl}acetamide; N-hydroxy-2-{1-methyl-3-[({4-[(2-methyl-4-quinolinyl)methoxy]phenyl}sulfonyl)methyl]-3-piperidinyl}acetamide; N-hydroxy-2-{1-isopropyl-3-[({4-[(2-methyl-4-quinolinyl)methoxy]phenyl}sulfonyl)methyl]-3-piperidinyl}acetamide; N-hydroxy-2-{1-isobutyl-3-[({4-[(2-methyl-4-quinolinyl)methoxy]phenyl}sulfonyl)methyl]-3-piperidinyl}acetamide; N-hydroxy-2-{4-[({4-[(2-methyl-4-quinolinyl)methoxy]phenyl}sulfonyl)methyl]-4-piperidinyl}acetamide; N-hydroxy-2-{1-methyl-4-[({4-[(2-methyl-4-quinolinyl)methoxy]phenyl}sulfonyl)methyl]-4-piperidinyl}acetamide; N-hydroxy-2-{2-[({4-[(2-methyl-4-quinolinyl)methoxy]phenyl}sulfonyl)methyl]tetrahydro-2-furanyl}acetamide; N-hydroxy-2-{1-methyl-3-[({4-[(2-methyl-4-quinolinyl)methoxy]phenyl}sulfonyl)methyl]-2-oxopyrrolidinyl}acetamide; N-hydroxy-2-[5-[({4-[(2-methyl-4-quinolinyl)methoxy]phenyl}sulfonyl)methyl]-3-(3-pyridinyl)4,5-dihydro-5-isoxazolyl]acetamide; N-hydroxy-2-[5-[({4-[(2methyl-4-quinolinyl)methoxy]phenyl}sulfonyl)methyl]-3-(4-pyridinyl)-4,5-dihydro-5-isoxazolyl]acetamide and, N-hydroxy-2-{4-[({4-[(2-methyl-4-quinolinyl)methoxy]phenyl}sulfonyl)methyl]tetrahydro-2H-pyran-4-yl}acetamide; or a pharmaceutically acceptable salt form thereof.
- 6. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt form thereof.
- 7. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound according to claim 2 or a pharmaceutically acceptable salt form thereof.
- 8. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound according to claim 3 or a pharmaceutically acceptable salt form thereof.
- 9. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound according to claim 4 or a pharmaceutically acceptable salt form thereof.
- 10. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound according to claim 5 or a pharmaceutically acceptable salt form thereof.
- 11. A method of treating a disease or condition in a patient, comprising: administering to the mammal in need of such treatment a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt form thereof, wherein the disease or condition is selected from cachexia, gingivitis, hemorrhage, multiple sclerosis, neovascular glaucoma, periodontitis, and solid tumor growth and tumor invasion by secondary metastases.
- 12. A method of treating a disease or condition in a patient, comprising: administering to the mammal in need of such treatment a therapeutically effective amount of a compound of claim 2 or a pharmaceutically acceptable salt form thereof, wherein the disease or condition is selected from cachexia, gingivitis, hemorrhage, multiple sclerosis, neovascular glaucoma, periodontitis, and solid tumor growth and tumor invasion by secondary metastases.
- 13. A method of treating a disease or condition in a patient, comprising: administering to the mammal in need of such treatment a therapeutically effective amount of a compound of claim 3 or a pharmaceutically acceptable salt form thereof, wherein the disease or condition is selected from cachexia, gingivitis, graft versus host disease, hemorrhage, multiple sclerosis, neovascular glaucoma, periodontitis, and solid tumor growth and tumor invasion by secondary metastases.
- 14. A method of treating a disease or condition in a patient, comprising: administering to the mammal in need of such treatment a therapeutically effective amount of a compound of claim 4 or a pharmaceutically acceptable salt form thereof, wherein the disease or condition is selected from cachexia, gingivitis, graft versus host disease, hemorrhage, multiple sclerosis, neovascular glaucoma, periodontitis, and solid tumor growth and tumor invasion by secondary metastases.
- 15. A method of treating a disease or condition in a patient, comprising: administering to the mammal in need of such treatment a therapeutically effective amount of a compound of claim 5 or a pharmaceutically acceptable salt form thereof, wherein the disease or condition is selected from cachexia, gingivitis, graft versus host disease, hemorrhage, multiple sclerosis, neovascular glaucoma, periodontitis, and solid tumor growth and tumor invasion by secondary metastases.
CROSS REFERENCE TO RELATED APPLICATIONS
This application claims the priority benefit of U.S. Provisional Application No. 60/260,952, filed Jan. 11, 2001, which is expressly incorporated fully herein by reference.
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
5179105 |
Igarashi et al. |
Jan 1993 |
A |
Foreign Referenced Citations (5)
Number |
Date |
Country |
780386 |
Jun 1997 |
EP |
818442 |
Jan 1998 |
EP |
WO 9720824 |
Jun 1997 |
WO |
WO 9732846 |
Sep 1997 |
WO |
WO 9839316 |
Sep 1998 |
WO |
Non-Patent Literature Citations (1)
Entry |
Steward, Marimastat (BB2516): Current status of development, Cancer Chemother Pharmacol. 43(Suppl):S56-S60, 1999. |
Provisional Applications (1)
|
Number |
Date |
Country |
|
60/260952 |
Jan 2001 |
US |